Department of Chemical Engineering, University of Texas, Austin, 78712, USA.
ACS Chem Biol. 2010 Mar 19;5(3):333-42. doi: 10.1021/cb900267j.
Replacing the two Mn(2+) ions normally present in human Arginase I with Co(2+) resulted in a significantly lowered K(M) value without a concomitant reduction in k(cat). In addition, the pH dependence of the reaction was shifted from a pK(a) of 8.5 to a pK(a) of 7.5. The combination of these effects led to a 10-fold increase in overall catalytic activity (k(cat)/K(M)) at pH 7.4, close to the pH of human serum. Just as important for therapeutic applications, Co(2+) substitution lead to significantly increased serum stability of the enzyme. Our data can be explained by direct coordination of l-Arg to one of the Co(2+) ions during reaction, consistent with previously reported model studies. In vitro cytotoxicity experiments verified that the Co(2+)-substituted human Arg I displays an approximately 12- to 15-fold lower IC(50) value for the killing of human hepatocellular carcinoma and melanoma cell lines and thus constitutes a promising new candidate for the treatment of l-Arg auxotrophic tumors.
将人精氨酸酶 I 中通常存在的两个 Mn(2+)离子替换为 Co(2+),导致 K(M) 值显著降低,而 k(cat)没有相应降低。此外,反应的 pH 依赖性从 pK(a)8.5 转移到 pK(a)7.5。这些效应的结合导致在 pH7.4 时整体催化活性 (k(cat)/K(M)) 增加了 10 倍,接近人血清的 pH 值。对于治疗应用同样重要的是,Co(2+)取代导致酶的血清稳定性显著增加。我们的数据可以通过在反应过程中 l-Arg 与 Co(2+)离子之一的直接配位来解释,这与之前报道的模型研究一致。体外细胞毒性实验证实,Co(2+)-取代的人 Arg I 对人肝癌和黑色素瘤细胞系的杀伤作用的 IC(50)值降低了约 12-15 倍,因此构成了治疗 l-Arg 营养缺陷型肿瘤的有前途的新候选药物。